IMPACT Therapeutics (英派药业) is a biopharmaceutical company engaged in the discovery and development of therapeutics to treat cancer and other life-threatening diseases. It offers a small-molecule drug discovery and development platform. The company's product pipeline includes PARP inhibitors, Wee1 inhibitors, other DDR target inhibitors, and Hedgehog pathway inhibitors.